174 related articles for article (PubMed ID: 30675075)
21. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
Bergua JM; Montesinos P; Martinez-Cuadrón D; Fernández-Abellán P; Serrano J; Sayas MJ; Prieto-Fernandez J; García R; García-Huerta AJ; Barrios M; Benavente C; Pérez-Encinas M; Simiele A; Rodríguez-Macias G; Herrera-Puente P; Rodríguez-Veiga R; Martínez-Sánchez MP; Amador-Barciela ML; Riaza-Grau R; Sanz MA;
Br J Haematol; 2016 Sep; 174(5):700-10. PubMed ID: 27118319
[TBL] [Abstract][Full Text] [Related]
22. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Gemici A; Ozkalemkas F; Dogu MH; Tekinalp A; Alacacioglu I; Guney T; Ince I; Geduk A; Cagliyan GA; Maral S; Serin I; Gunduz E; Karakus V; Bekoz HS; Eren R; Pinar IE; Gunes AK; Sargın FD; Sevindik OG
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e686-e692. PubMed ID: 34059487
[TBL] [Abstract][Full Text] [Related]
23. Prolonged administration of low-dose cytarabine and thioguanine in elderly patients with acute myeloid leukaemia (AML) achieves high complete remission rates and prolonged survival.
Arthur C; Jeffrey A; Yip E; Katsioulas V; Nalpantidis A; Kerridge I; Greenwood M; Coyle L; Mackinlay N; Fay K; Enjeti A; Shortt J; Stevenson W
Leuk Lymphoma; 2020 Apr; 61(4):831-839. PubMed ID: 31809629
[TBL] [Abstract][Full Text] [Related]
24. Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older.
Vives S; Oriol A; Piernas S; Brunet S; Clapés V; Guardia R; Subirà M; Sierra J; Ribera JM;
Eur J Haematol; 2015 Dec; 95(6):576-82. PubMed ID: 25692738
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission.
Mao C; Fu XH; Yuan JQ; Yang ZY; Huang YF; Ye QL; Wu XY; Hu XF; Zhai ZM; Tang JL
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010248. PubMed ID: 26544114
[TBL] [Abstract][Full Text] [Related]
26. Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO).
Kahl C; Krahl R; Becker C; Al-Ali HK; Sayer HG; Schulze A; Herold M; Hänel M; Scholl S; Hochhaus A; Uharek L; Maschmeyer G; Haehling D; Junghanß C; Peter N; Kämpfe D; Kettner E; Heinicke T; Fischer T; Kreibich U; Wolf HH; Niederwieser D
J Cancer Res Clin Oncol; 2016 Jan; 142(1):305-15. PubMed ID: 26407768
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy Comparison of Different Salvage Treatment Regimens for Patients with Refractory/Relapsed Acute Myeloid Leukemia].
Gao WH; Li HM; Yu JY; Zheng YL; Wu LH; Liu QG; Li JF; Liu CH; Hu YM; Xu N; Li SZ; Mi YC; Huang PP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):340-345. PubMed ID: 28446272
[TBL] [Abstract][Full Text] [Related]
28. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
[TBL] [Abstract][Full Text] [Related]
29. A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia.
Getz KD; Miller TP; Seif AE; Li Y; Huang YS; Bagatell R; Fisher BT; Aplenc R
Cancer Med; 2015 Sep; 4(9):1356-64. PubMed ID: 26105201
[TBL] [Abstract][Full Text] [Related]
30. Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results.
Wieduwilt MJ; Pawlowska N; Thomas S; Olin R; Logan AC; Damon LE; Martin T; Kang M; Sayre PH; Boyer W; Gaensler KML; Anderson K; Munster PN; Andreadis C
Clin Cancer Res; 2019 Aug; 25(16):4917-4923. PubMed ID: 31152020
[TBL] [Abstract][Full Text] [Related]
31. A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China.
Wang J; Lü S; Yang J; Song X; Chen L; Huang C; Hou J; Zhang W
J Hematol Oncol; 2009 Jul; 2():32. PubMed ID: 19642997
[TBL] [Abstract][Full Text] [Related]
32. [Clinical Analysis of Elderly Patients with AML/High-Risk MDS].
Xu WY; Wang F; Liu L; Ren XH; Liu PP; Zhang H; Zheng L; Zhang SS; Xu YR; Guo ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1311-1317. PubMed ID: 36208228
[TBL] [Abstract][Full Text] [Related]
33. Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukaemia: a multicentre, phase II study.
Manoharan A; Reynolds J; Matthews J; Baxter H; Di Iulio J; Leahy M; Juneja S;
Drugs Aging; 2007; 24(6):481-8. PubMed ID: 17571913
[TBL] [Abstract][Full Text] [Related]
34. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
Tenold ME; Moskoff BN; Krishnan R; Rosenberg AS; Hoeg RT; Abedi M; Tuscano JM; Jonas BA
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e611-e618. PubMed ID: 33811007
[TBL] [Abstract][Full Text] [Related]
35. Impact of Blood Count Recovery-based Complete Remission Before Allogeneic Hematopoietic Stem Cell Transplantation on Survival in Patients With Acute Myeloid Leukemia.
Ciftciler R; Demiroglu H; Buyukasık Y; Aksu S; Goker H
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):e205-e212. PubMed ID: 30665867
[TBL] [Abstract][Full Text] [Related]
36. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
[TBL] [Abstract][Full Text] [Related]
37. Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.
Bouchacourt B; Hospital MA; Zemmour C; Rey J; d'Incan E; Charbonnier A; Mohty B; Saillard C; Bonnet S; Collignon A; Gelsi-Boyer V; Mozziconacci MJ; Blaise D; Vey N
Ann Hematol; 2020 Apr; 99(4):773-780. PubMed ID: 32088745
[TBL] [Abstract][Full Text] [Related]
38. Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia.
Reid JH; Marini BL; Benitez LL; Pettit K; Bixby DL; Burke P; Perissinotti AJ
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):393-400.e1. PubMed ID: 33612433
[TBL] [Abstract][Full Text] [Related]
39. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
40. Elderly patients with acute myeloid leukaemia: characteristics in biology, patients and treatment. Recommendations of the Working Group Geriatric Oncology of the German Society for Haematology and Oncology (DGHO), the Austrian Society for Haematology and Oncology (OGHO) and the German Society for Geriatrics (DGG).
Wedding U; Bokemeyer C; Meran JG; ; ;
Onkologie; 2004 Feb; 27(1):72-82. PubMed ID: 15007253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
